Dec 10, 2019 ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
Nov 7, 2019 ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease
Nov 7, 2019 ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Oct 24, 2019 ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease